BackCelyad Oncology S.A. Overview

Celyad Oncology S.A. Receivables

Track Celyad Oncology S.A.'s receivables ($730K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$728000.00
↓ 4.21% YoYΔ $-32000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Celyad Oncology S.A. Receivables History

Loading

Celyad Oncology S.A. vs. peers: Receivables Comparison

Loading

Celyad Oncology S.A. Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Celyad Oncology S.A. (CLYYF) FAQ

Celyad Oncology S.A. posts a receivables of $730K as of June 2026. That compares with $760K in the prior-year period — down 4.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Celyad Oncology S.A.'s receivables was $760K. The latest reading is $730K — a 4.2% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Celyad Oncology S.A.'s financial statement story. At $730K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CLYYF's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Celyad Oncology S.A.'s other metric pages and overview cover the third.

Judging Celyad Oncology S.A. against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $730K here, then scan peer and history charts to see if the gap is persistent.